Taylor H C, Santa-Cruz D, Teitelbaum S L, Bergfeld M A, Whyte M P
Division of Endocrinology, Lutheran Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio 44113.
Bone. 1988;9(1):37-43. doi: 10.1016/8756-3282(88)90025-7.
A 57 year old white male with oncogenous osteomalacia due to a mixed mesenchymal tumor was evaluated by sequential histologic and metabolic studies over a period of 33 mos prior to identifying the location of the tumor. On the basis of these studies we conclude: (i) disorders of the enterohepatic circulation and/or acceleration of metabolism of calcitriol are not responsible for its diminished level in oncogenous osteomalacia, (ii) the Von Kossa stain is preferred to the modified Masson in evaluating osteomalacia, (iii) avascular necrosis of the femoral head may be part of the syndrome, (iv) heterogeneity may be the hallmark of the responsible mesenchymal tumor and account for the different histological interpretations in the literature, (v) in compliant patients with oncogenous osteomalacia, calcitriol and Pi therapy may be effective.
一名57岁的白人男性因混合性间充质肿瘤导致肿瘤性骨软化症，在确定肿瘤位置之前的33个月内，通过连续的组织学和代谢研究进行了评估。基于这些研究，我们得出以下结论：（i）肠肝循环紊乱和/或骨化三醇代谢加速并非肿瘤性骨软化症中其水平降低的原因；（ii）在评估骨软化症时，冯·科萨染色比改良马松染色更可取；（iii）股骨头缺血性坏死可能是该综合征的一部分；（iv）异质性可能是相关间充质肿瘤的标志，并解释了文献中不同的组织学解释；（v）在依从性好的肿瘤性骨软化症患者中，骨化三醇和磷治疗可能有效。
